Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.
Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
Eur Urol Oncol. 2023 Jun;6(3):303-310. doi: 10.1016/j.euo.2023.03.005. Epub 2023 Apr 1.
Management of local recurrence of prostate cancer (PCa) in the prostatic bed after radical prostatectomy (RP) and radiotherapy remains challenging.
To assess the efficacy and safety of salvage stereotactic body radiotherapy (SBRT) reirradiation in this setting and evaluate prognostic factors.
DESIGN, SETTING, AND PARTICIPANTS: We conducted a large multicenter retrospective series that included 117 patients who were treated with salvage SBRT for local recurrence in the prostatic bed after RP and radiotherapy in 11 centers across three countries.
Progression-free survival (PFS; biochemical, clinical, or both) was estimated using the Kaplan-Meier method. Biochemical recurrence was defined as prostate-specific antigen nadir +0.2 ng/ml, confirmed by a second increasing measure. The cumulative incidence of late toxicities was estimated using the Kalbfleisch-Prentice method by considering recurrence or death as a competing event.
The median follow-up was 19.5 mo. The median SBRT dose was 35 Gy. The median PFS was 23.5 mo (95% confidence interval [95% CI], 17.6-33.2). In the multivariable models, the volume of the recurrence and its contact with the urethrovesical anastomosis were significantly associated with PFS (hazard ratio [HR]/10 cm = 1.46; 95% CI, 1.08-1.96; p = 0.01 and HR = 3.35; 95% CI, 1.38-8.16; p = 0.008, respectively). The 3-yr cumulative incidence of grade ≥2 late GU or GI toxicity was 18% (95% CI, 10-26). In the multivariable analysis, a recurrence in contact with the urethrovesical anastomosis and D2% of the bladder were significantly associated with late toxicities of any grade (HR = 3.65; 95% CI, 1.61-8.24; p = 0.002 and HR/10 Gy = 1.88; 95% CI, 1.12-3.16; p = 0.02, respectively).
Salvage SBRT for local recurrence in the prostate bed may offer encouraging control and acceptable toxicity. Therefore, further prospective studies are warranted.
We found that salvage stereotactic body radiotherapy after surgery and radiotherapy allows for encouraging control and acceptable toxicity in locally relapsed prostate cancer.
根治性前列腺切除术(RP)和放疗后前列腺床局部复发性前列腺癌(PCa)的管理仍然具有挑战性。
评估挽救性立体定向体放射治疗(SBRT)再放疗在这种情况下的疗效和安全性,并评估预后因素。
设计、地点和参与者:我们进行了一项大型多中心回顾性系列研究,该研究纳入了 11 个中心的 117 例患者,这些患者在 3 个国家的 11 个中心接受了挽救性 SBRT 治疗 RP 和放疗后前列腺床局部复发。
使用 Kaplan-Meier 方法估计无进展生存率(PFS;生化、临床或两者兼有)。生化复发定义为前列腺特异性抗原最低点+0.2ng/ml,并通过第二次增加测量得到证实。使用 Kalbfleisch-Prentice 方法估计晚期毒性的累积发生率,将复发或死亡视为竞争事件。
中位随访时间为 19.5 个月。SBRT 剂量中位数为 35Gy。中位 PFS 为 23.5 个月(95%置信区间[95%CI],17.6-33.2)。在多变量模型中,复发的体积及其与尿道膀胱吻合口的接触与 PFS 显著相关(危险比[HR]/10cm=1.46;95%CI,1.08-1.96;p=0.01 和 HR=3.35;95%CI,1.38-8.16;p=0.008)。3 年累积发生率为≥2 级晚期 GU 或 GI 毒性为 18%(95%CI,10-26)。在多变量分析中,与尿道膀胱吻合口接触的复发和膀胱 D2%与任何等级的晚期毒性显著相关(HR=3.65;95%CI,1.61-8.24;p=0.002 和 HR/10Gy=1.88;95%CI,1.12-3.16;p=0.02)。
挽救性 SBRT 治疗前列腺床局部复发可能提供令人鼓舞的控制和可接受的毒性。因此,需要进一步的前瞻性研究。
我们发现,手术和放疗后行挽救性立体定向体放射治疗可在局部复发性前列腺癌中获得令人鼓舞的控制和可接受的毒性。